Pathogen | Intervention | n | Median | HR | 95% CI | P value* |
hours | ||||||
ETEC† | PTM202 | 16 | 27.0 | 1.86 | 0.93 to 3.70 | 0.08 |
Placebo | 21 | 35.8 | ||||
STEC/0157† | PTM202 | 5 | 3.0 | 12.17 | 1.38 to 107.84 | 0.025 |
Placebo | 6 | 28.9 | ||||
Rotavirus† | PTM202 | 6 | 20.1 | 1.38 | 0.41 to 4.67 | 0.60 |
Placebo | 6 | 41.5 | ||||
Salmonella† | PTM202 | 1 | N/A | 2.45 | 0.15 to 39.72 | 0.53 |
Placebo | 3 | 41.9 | ||||
Norovirus‡ | PTM202 | 26 | 24.6 | 1.66 | 0.94 to 2.94 | 0.08 |
Placebo | 27 | 30.9 | ||||
Shigella (EIEC)‡ | PTM202 | 14 | 25.6 | 2.52 | 0.88 to 7.23 | 0.09 |
Placebo | 7 | 41.1 | ||||
Campylobacter | PTM202 | 16 | 25.0 | 1.67 | 0.74 to 3.78 | 0.22 |
Placebo | 11 | 39.8 | ||||
Clostridium difficile | PTM202 | 5 | 22.6 | 6.43 | 1.17 to 35.29 | 0.03 |
Placebo | 7 | 30.9 | ||||
Plesiomonas | PTM202 | 1 | N/A | N/A | N/A | N/A |
Placebo | 1 | N/A | ||||
Enteroaggregative Escherichia coli | PTM202 | 33 | 25.6 | 1.15 | 0.71 to 1.89 | 0.57 |
Placebo | 32 | 30.1 | ||||
Enteropathogenic E. coli | PTM202 | 27 | 25.6 | 1.63 | 0.94 to 2.83 | 0.08 |
Placebo | 29 | 30.9 | ||||
Cryptosporidium | PTM202 | 3 | 19.0 | 1.70 | 0.34 to 8.62 | 0.52 |
Placebo | 4 | 33.9 | ||||
Giardia | PTM202 | 7 | 5.2 | 2.27 | 0.47 to 11.04 | 0.31 |
Placebo | 3 | 17.2 | ||||
Adenovirus | PTM202 | 8 | 23.4 | 1.53 | 0.52 to 4.50 | 0.44 |
Placebo | 7 | 65.7 | ||||
Astrovirus* | PTM202 | 3 | 22.6 | 2.09 | 1.57 to 2.79 | <0.0001 |
Placebo | 3 | 46.3 | ||||
Sapovirus | PTM202 | 7 | 35.8 | 0.89 | 0.31 to 2.55 | 0.83 |
Placebo | 9 | 41.4 |
*HR not calculable due to bimodal distribution of the data; risk ratio using Poisson distribution is presented.
†Organism directly targeted by PTM202.
‡Organism indirectly targeted by PTM202.
EIEC, enteroinvasive E.coli; ETEC, enterotoxigenic E.coli.